Article
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Oncology - 1 Jan 2007
Underhill Craig, Goldstein David, Gorbounova Vera A, Biakhov Mikhail Y, Bazin Igor S, Granov Dmitry A, Hossain Anwar M, Blatter Johannes, Kaiser Christopher, Ma Doreen
Abstract excerpt
BACKGROUND: This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer. Secondary objectives included overall and progression-free survival, duration of response, toxicities, and biomarkers. PATIENTS AND METHODS: ALIRI patients received pemetrexed 500...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.